Ultragenyx is planning to build a 100,000-sf gene therapy manufacturing facility in Bedford, Mass. Accommodating two independent production suites with a capacity of 30 runs per year, the project will leverage 2,000-liter bioreactors and the company's HEK293 transient transfection system to support the large-scale manufacture of clinical-stage materials and approved products based on adeno-associated viral vectors (AAV). Leveraging a highly reproducible and scalable platform, the facility will accelerate the availability of innovative treatments for rare genetic diseases. Site work began in fall of 2020 and completion is expected in 2023. Based in Novato, Calf., Ultragenyx is also planning a subsequent phase of development at the Bedford site that will provide an additional 86,000 sf of production capacity.